Typical consumers don’t think or talk about cannabis lab testing.
What do you mean by lab testing? Like, all that microscopic writing on the labels stuck on tubes and jars?
The details are about as relevant to daily life as all the information on a mattress label—that is to say quite a bit, since we don’t want to be sleeping on or smoking toxic garbage, still we trust that those responsible for manufacturing, analyzing, and regulating products like these are competent.
Yet when it comes to marijuana product testing in the Bay State, there hasn’t been much order, rhyme, or reason. Due to loose and inconsistent protocols and requirements over the first decade of regulated cannabis, ambiguity has grown into a demonstrable problem. That has manifested via lawsuits between ITLs, accusations of market manipulation, HR rifts at the Cannabis Control Commission, and even some concern among the public, which otherwise wouldn’t have paid a damn lick of attention to this stuff.
None of that’s to say that lives are in danger. It is weed after all, and while testing for heavy metals and other contaminants are important and part of this wide-ranging discussion at the agency, the goal of straightening out testing in the commonwealth is bigger than just public health. As CCC members took up the conversation last week about proposed new regulations, issues including industry sustainability are also front and center.
It’s going to be an extremely complicated, and perhaps somewhat contentious monthslong affair. Offering a glimpse of what’s to come, at last Thursday’s public meeting Commissioner Anthony Wilson described himself as “very much a proponent for more intensive thorough testing,” but noted, “I think at this [proposed testing] frequency it would be damaging to the market and to our licensees. So I just want to put that on the record.”
We hope to highlight nuances and small observations along the way to promulgation of new testing regulations. We’ll also be publishing analyses and opinions from industry experts and scientists. With the conversation ongoing, we also recommend that readers who wish to follow closely peruse the commission’s raw materials—from the extensive media release that we reprinted below, to the actual proposal.
“I want to note that today’s discussion is intended to inform potential policy and regulatory approaches under consideration by the commission,” Chair Christopher Harding said last Thursday. “The commission does anticipate opening a formal public comment period in January, which will provide independent testing labs and other interested stakeholders an opportunity to formally weigh in on any proposed regulatory changes and submit feedback for the commission’s consideration.”
In other words, the chair explained, “you get more than one lick at the lollipop here. … So, we’ve got more opportunity, but we do need to move this forward. We are on the clock and we know it’s an incredibly important topic.”
Commissioner Xiomara Albán DeLobato added, “Whatever direction we go, it’s going to be fair game for us to hear from the public on feedback on whether this is a great direction to go to or if it’s not.”
CCC Assoc. General Counsel Erica Bruno said, “This represents a comprehensive modernization of the Massachusetts regulatory framework for marijuana product testing. These regulations establish more detailed and standardized requirements governing how regulatory compliance testing is conducted, including analytical performance standards, method validation and verification, quality control, and laboratory accreditation requirements.”
Bruno continued, “While this draft is a great start, the working group does have additional areas that we will be proposing for future work in the spring of 2027. We look forward to further developing those for future consideration for the commission. So, this is definitely a wonderful jumping off point. Significant amounts of work to do, but we know there’s still more to accomplish. There were some areas that we know are important focuses that we just were not able to cover in the expedited timeline that we have.”
The media release below was provided by the CCC:
The Cannabis Control Commission (Commission) at Thursday’s public meeting advanced new cannabis testing regulations that will modernize requirements for compliance testing and put Massachusetts on the forefront of cannabis testing standards nationwide.
The new draft testing regulations were released at the Oct. 22 meeting, allowing Commissioners to consider important policy questions, including which cannabis and cannabis products require testing, when testing must occur and how Independent Testing Labs (ITLs) reanalyze products that fail testing.
The draft regulations expand the Commission’s testing requirements and create a new section under 935 CMR dedicated entirely to cannabis testing to support public health and safety. The draft regulations also fulfill new requirements under Ch. 65 of the Acts of 2026 (Ch.65) and follow a holistic review of testing protocols incorporating feedback from an informal public comment period and public hearing held in August, feedback from a previous ITL listening session, and meetings with ITL owners
“These new regulations are intended to reduce variability in testing, improve the accuracy and reliability of test results, and strengthen the Commission’s ability to identify testing deficiencies and take necessary enforcement actions,” Chair Chris Harding said. “These changes fulfill our duty under Ch. 65 of the Acts of 2026 but, more importantly, will strengthen trust in the products available on the state’s medical and adult-use marketplaces.”
“Modernizing testing regulations is a priority for the Commission, and we anticipate continuing to add new updates in 2027, including sampling and pesticides,” said Commissioner Anthony Wilson, who leads an internal working group focused on cannabis testing. “For consumers and patients, the proposed regulations will reinforce final form testing requirements, providing important safeguards as cannabis and cannabis products pass from cultivators to manufacturers and into retail stores and treatment centers.”
“The Massachusetts cannabis industry recently marked major milestones like reaching $10 billion in sales and overcoming a repeal effort by ballot measure,” Commissioner Xiomara Albán DeLobato said. “Those milestones were possible thanks to the industry operating safely under the Commission’s oversight, building trust with patients and consumers. These new testing regulations create a standard framework that takes our commitment of leading a safe industry to the next level.”
The policy questions decided by Commissioners at Thursday’s meeting include:
- Requiring regulatory compliance testing prior to any sale conducted business to business or business to consumer;
- Transitioning to targeted microbial speciation testing for specified organisms of public health concern;
- Establishing standards for ITLs to automatically retest failures prior to issuing Certificates of Authenticity (COAs) to confirm the validity of initial failed results and distinguish actual regulatory noncompliance from potential lab errors;
- Eliminating the Standards Laboratory license type;
- Requiring product labels to identify if products have been sanitized or remediated; and
- Establishing that new testing regulations under 935 CMR 503.000 will go into effect six months after promulgation, tentatively scheduled for April 2027.
Commissioners are expected to approve the draft testing regulations in December alongside other updates considered at meetings throughout September and October. The Commission will accept feedback on all those regulations beginning in January during a wider public comment process for regulatory updates related to Ch. 65 implementation.
“Although this is the first update of cannabis compliance testing regulations since the Commission’s founding, Commissioners and staff have been hard at work over the years ensuring that products available to consumers and patients are safe,” Executive Director Travis Ahern said. “The Commission is looking forward to hearing from the public as we move toward promulgating these new testing regulations and other important updates made in recent months in early 2027.”
The draft testing regulations—and future updates planned in 2027—are the culmination of testing efforts carried out over the last several years including:
- Conducting a THC potency audit and releasing results that required corrective actions for noncompliant products as part of the Commission’s oversight efforts;
- Centralizing testing-related materials on a new Testing and Analysis webpage;
- Publishing test results for total THC to the agency’s Open Data platform;
- Creating an ongoing, internal task force focused on testing;
- Updating Secret Shopper program regulations to allow third-party vendors or contractors—such as nonprofits, research institutions, and other legal entities—to enter into agreements with the Commission to act as secret shoppers;
- Requiring ITLs to upload digital COAs after every test to document methods labs use to test products in compliance with regulations, and working with Metrc, the seed-to-sale tracking system, to make those COAs available to consumers and patients;
- Creating the Public Health and Safety Advisories web portal, where consumers and patients can view products flagged for health and safety issues;
- Requiring licensed adult- and medical-use cannabis businesses to submit one test sample package to a single ITL for all compliance testing; and
- Convened a public listening session with ITLs and the public to hear concerns about testing regulations.
Information about compliance testing can be found on the Commission’s Testing and Analysis page. Commission meetings and public hearings can be found on the calendar page or by contacting the Commission by phone (774-415-0200) or email (Commission@CCCMass.com), or following the agency on Facebook, LinkedIn, and X.